NAtive Collagen Type II In Healthy VoluntEers With Joint Discomfort (ACTIVE)
Primary Purpose
Joint Pain
Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Native type II collagen
Placebo
Sponsored by
About this trial
This is an interventional other trial for Joint Pain
Eligibility Criteria
Inclusion Criteria:
- Males and non-pregnant females 30-65 years old with a Body Mass Index (BMI) of approximately 18 to 30 kg/m2. (see Section 4.0)
- Unilateral or bilateral knee discomfort for greater than 3 months.
- VAS score during knee movement between 30-50 mm after 7-day withdrawal of excluded medications.
- Reach joint discomfort of 5/10 on a 11-point Likert scale ( score 0 to 10) within 10 minutes of going up and down stairs.
- Clinical laboratory results that are within normal range or considered not clinically significant by the Principal Investigator.
- Be willing to participate in all scheduled visits, tests, and other trial procedures according to the clinical protocol. To do so and be able of using the fitness tracker, a phone or tablet compatible with the Fitbit app is required. (Apple iOS 12.2 or higher, Android OS 7.0 or higher.)
- Be willing to refrain from taking ibuprofen, aspirin or other Non-steroidal anti-inflammatory drugs (NSAIDs), or any other pain reliever (OTC (Over the Counter) or prescription) during the entire study other than acetaminophen (paracetamol) as rescue medication.
- Provide a signed and dated informed consent indicating that the subject has been informed of all pertinent aspects and possible risks associated with participation in the study.
- Be willing to refrain from taking dietary supplements during the entire study that have any underlying joint benefit (collagen, glucosamine, chondroitin, MSM, Hyaluronic Acid, Turmeric, Natural Eggshell Membrane, Omega-3 fatty acids, PEA, Boswellia,…)
Exclusion Criteria:
- History of hypersensitivity to the rescue medication or any of the products used in the study.
- Requirement of drugs to control joint discomfort.
- Regular drug intake to control any kind of pain.
- History of hypersensitivity to eggs, chicken, or fowl.
- History of Knee OA (OsteoArthritis), inflammatory arthropathy, RA (Rheumatoid Arthritis), OA (VAS score greater than 50), or Systemic Lupus Erythematosus.
- Hyperuricemia (>440 μmol/L), history of gout, or both.
- Exercising (intentionally) for more than 10 hours a week
- High intensity exercise for more than 5 hours a week
- Anticipation of surgery within the next 6 months.
- Recent injury in the target knee (past 4 months).
- History of congestive heart failure.
- Anticipated problems with product consumption.
- Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, or malignancies within the last 5 years.
- High alcohol intake (>2 standard drinks per day) or use of recreational drugs (e.g., cocaine, methamphetamine, marijuana, etc.).
- Females who are pregnant or lactating or planning to become pregnant.
- History of any mental illness that might impair the ability of subjects to provide a written informed consent.
- Use of oral corticosteroid, indomethacin, SYSADOAs (symptomatic slow action drug osteoarthritis) within 3 months of Visit 1; topical treatment with corticosteroids within 1 week of visit 1, and consumption of Omega 3 fatty acids or any other joint health dietary supplements within 2 weeks preceding the treatment period.
- Consumed, ibuprofen, aspirin or other NSAIDS, or any other pain reliever (OTC or prescription), or any natural health product, (excluding vitamins) within 7 days of first visit.
- Consumed acetaminophen (paracetamol) within 48 hours of randomization visit.
- Participation in any clinical trials within 30 days prior to first visit.
- Individuals following an energy restricted diet for weight loss
Sites / Locations
- Instituto Poal de ReumatologíaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Native type II collagen
Placebo
Arm Description
Native type II collagen
Placebo
Outcomes
Primary Outcome Measures
Change in joint discomfort onset
Determine differences from baseline on reaching a joint pain of 5/1 while going up and down stairs (max 10 min).
Secondary Outcome Measures
Joint discomfort
Visual Analog Scale (VAS, 0-10cm) pain at rest and during activity. A higher VAS means higher pain levels
Joint function
Knee injury and Osteoarthritis Outcome Score (KOOS) test
Time to Joint discomfort
Time to joint discomfort and to recover from pain in 3 different exercises
6 minute walking timed test (6MWT)
Distance a person is capable of walking on a flat, hard surface in 6 minutes
Rescue medication consumption
Rescue medication: Paracetamol 500mg. max 2 pills/day
Cartilage turnover biomarkers
Cartilage turnover biomarkers will be measured in blood and urine (CTX-II, C2C, CPII)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05282992
Brief Title
NAtive Collagen Type II In Healthy VoluntEers With Joint Discomfort
Acronym
ACTIVE
Official Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Tolerability of a Food Supplement in Healthy Volunteers With Joint Discomfort
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 3, 2022 (Actual)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
September 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bioiberica
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Collagen Supplement is a natural ingredient that contains native collagen derived from chicken sternum. Collagen Supplement is efficacious and safe on healthy subjects as compared to placebo.
Detailed Description
This study will include 100 healthy volunteers in which will be evaluated if the collagen supplement is able to obtain differences versus placebo in pain and function. It will be a randomized, double-blind, placebo-controlled study with proportion 1:1 between treatments
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Joint Pain
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Native type II collagen
Arm Type
Experimental
Arm Description
Native type II collagen
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Native type II collagen
Intervention Description
1 capsule/day
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
1 capsule/day
Primary Outcome Measure Information:
Title
Change in joint discomfort onset
Description
Determine differences from baseline on reaching a joint pain of 5/1 while going up and down stairs (max 10 min).
Time Frame
Change in joint discomfort onset at 6 months
Secondary Outcome Measure Information:
Title
Joint discomfort
Description
Visual Analog Scale (VAS, 0-10cm) pain at rest and during activity. A higher VAS means higher pain levels
Time Frame
Day 0 to day 60, 90, 120, 180
Title
Joint function
Description
Knee injury and Osteoarthritis Outcome Score (KOOS) test
Time Frame
Day 0 to day 60, 90, 120, 180
Title
Time to Joint discomfort
Description
Time to joint discomfort and to recover from pain in 3 different exercises
Time Frame
Day 0 to day 60, 90, 120, 180
Title
6 minute walking timed test (6MWT)
Description
Distance a person is capable of walking on a flat, hard surface in 6 minutes
Time Frame
Day 0 and 180
Title
Rescue medication consumption
Description
Rescue medication: Paracetamol 500mg. max 2 pills/day
Time Frame
Day 0 to 180, anytime
Title
Cartilage turnover biomarkers
Description
Cartilage turnover biomarkers will be measured in blood and urine (CTX-II, C2C, CPII)
Time Frame
Day 0 and 180
Other Pre-specified Outcome Measures:
Title
Daily activity levels
Description
A fitness tracker will monitor the steps taken daily
Time Frame
Day 0 to 180, anytime
Title
Muscle quality
Description
Muscle quality will be evaluated by an ultrasound index
Time Frame
Day 0 and 180
Title
Safety assessment
Description
Adverse events
Time Frame
Day 0 to 180, anytime
Title
Safety assessment
Description
Medical exams (weight in kilograms, height in meters, BMI in kg/m^2)
Time Frame
Day 0 to day 60, 90, 120, 180
Title
Safety assessment
Description
Vital signs (heart rate in bpm and blood pressure mmHg)
Time Frame
Day 0 to day 60, 90, 120, 180
Title
Safety assessment
Description
Laboratory analysis (total blood count, glucose, AST, ALT, Cholesterol, Creatinine, BUN, triglycerides, alkaline phosphatase)
Time Frame
Day 0 and 180
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Males and non-pregnant females 30-65 years old with a Body Mass Index (BMI) of approximately 18 to 30 kg/m2. (see Section 4.0)
Unilateral or bilateral knee discomfort for greater than 3 months.
VAS score during knee movement between 30-50 mm after 7-day withdrawal of excluded medications.
Reach joint discomfort of 5/10 on a 11-point Likert scale ( score 0 to 10) within 10 minutes of going up and down stairs.
Clinical laboratory results that are within normal range or considered not clinically significant by the Principal Investigator.
Be willing to participate in all scheduled visits, tests, and other trial procedures according to the clinical protocol. To do so and be able of using the fitness tracker, a phone or tablet compatible with the Fitbit app is required. (Apple iOS 12.2 or higher, Android OS 7.0 or higher.)
Be willing to refrain from taking ibuprofen, aspirin or other Non-steroidal anti-inflammatory drugs (NSAIDs), or any other pain reliever (OTC (Over the Counter) or prescription) during the entire study other than acetaminophen (paracetamol) as rescue medication.
Provide a signed and dated informed consent indicating that the subject has been informed of all pertinent aspects and possible risks associated with participation in the study.
Be willing to refrain from taking dietary supplements during the entire study that have any underlying joint benefit (collagen, glucosamine, chondroitin, MSM, Hyaluronic Acid, Turmeric, Natural Eggshell Membrane, Omega-3 fatty acids, PEA, Boswellia,…)
Exclusion Criteria:
History of hypersensitivity to the rescue medication or any of the products used in the study.
Requirement of drugs to control joint discomfort.
Regular drug intake to control any kind of pain.
History of hypersensitivity to eggs, chicken, or fowl.
History of Knee OA (OsteoArthritis), inflammatory arthropathy, RA (Rheumatoid Arthritis), OA (VAS score greater than 50), or Systemic Lupus Erythematosus.
Hyperuricemia (>440 μmol/L), history of gout, or both.
Exercising (intentionally) for more than 10 hours a week
High intensity exercise for more than 5 hours a week
Anticipation of surgery within the next 6 months.
Recent injury in the target knee (past 4 months).
History of congestive heart failure.
Anticipated problems with product consumption.
Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, or malignancies within the last 5 years.
High alcohol intake (>2 standard drinks per day) or use of recreational drugs (e.g., cocaine, methamphetamine, marijuana, etc.).
Females who are pregnant or lactating or planning to become pregnant.
History of any mental illness that might impair the ability of subjects to provide a written informed consent.
Use of oral corticosteroid, indomethacin, SYSADOAs (symptomatic slow action drug osteoarthritis) within 3 months of Visit 1; topical treatment with corticosteroids within 1 week of visit 1, and consumption of Omega 3 fatty acids or any other joint health dietary supplements within 2 weeks preceding the treatment period.
Consumed, ibuprofen, aspirin or other NSAIDS, or any other pain reliever (OTC or prescription), or any natural health product, (excluding vitamins) within 7 days of first visit.
Consumed acetaminophen (paracetamol) within 48 hours of randomization visit.
Participation in any clinical trials within 30 days prior to first visit.
Individuals following an energy restricted diet for weight loss
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ingrid Moller, MD
Phone
934 34 01 92
Email
ingrid.moller@ipoal.com
Facility Information:
Facility Name
Instituto Poal de Reumatología
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingrid Möller, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
NAtive Collagen Type II In Healthy VoluntEers With Joint Discomfort
We'll reach out to this number within 24 hrs